8th RNA-Targeted Drug Discovery and Development Summit

Memo

RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative, cancer and rare disorders. In 2025 alone, the field has seen major collaborations, including Wayfinder Biosciences with Daiichi Sankyo, Ono Pharmaceutical with Reborna Biosciences, and xFOREST with Astellas Pharma-signaling growing momentum and industry confidence. Now in its 8th year, the RNA-Targeted Drug Discovery and Development Summit returns as the only dedicated industry forum addressing the unique challenges of RNA-targeted drug development across splice modulators, covalent drugs, proximity inducers and direct RNA binders. Join 25+ world-class speakers from leaders like PTC Therapeutics, ReviR Therapeutics, Remix Therapeutics, Rgenta Therapeutics, Arrakis Therapeutics and more this December to gain the connections, tools and scientific firepower needed to bring your RNA-targeted therapeutics to clinic and beyond. URLs:Tickets: https://go.evvnt.com/3181066-2?pid=5569Brochure: https://go.evvnt.com/3181066-3?pid=5569 Prices:Drug developer Pricing - Conference + 2 Workshops: USD 4197.00,Drug developer Pricing - Conference + 1 Workshop: USD 3598.00,Drug developer Pricing - Conference Only: USD 2999.00,Academic Pricing - Conference + 2 Workshops: USD 3597.00,Academic Pricing - Conference + 1 Workshop: USD 3098.00,Academic Pricing - Conference Only: USD 2599.00,Service Provider Pricing - Conference Only: USD 3699.00,Service Provider Pricing - Conference + 2 Workshops: USD 5097.00,Service Provider Pricing - Conference + 1 Workshop: USD 4398.00 Speakers: Adam Buckle, Chief Scientific Officer, Arrayjet, Amanda Hargrove, Professor of Chemistry, University of Toronto, Atsushi Shiomi, Director of Innovation Research Partnering, NS Pharma, Inc., Balajee Somalinga, Director of RNA Biology, CHDI Foundation, Brittany Morgan, Assistant Professor, University of Notre Dame, Christopher Trotta, Senior Vice President of Discovery Biology, PTC Therapeutics, David Sparkman-Yager, Chief Technology Officer, Wayfinder Biosciences, Dominic Reynolds, CSO, Remix Therapeutics, Elena Diez, Cecilia Senior Director of External Innovation, DPDS, Johnson and Johnson, Ella Czarina Morishita, Chief Scientific Officer, Veritas In Silico Inc., Jeffrey Kieft, Executive Director, New York Structural Biology Center, Jennifer Petter, Chief Scientific Officer, Arrakis Therapeutics Inc., Jerry McMahon, President and Chief Executive Officer, STORM Therapeutics Ltd., Jimin Hwang, Researcher, Pyle Lab at Yale University, Karen Wu, Chief Executive Officer and Co-Founder, Lucerna, Inc., Kevin Weeks, Distinguished Professor, Department of Chemistry, UNC at Chapel Hill, Ku-Lung (Ken) Hsu, Associate Professor, The University of Texas at Austin, Matt Woll, Senior Vice President of Chemistry, PTC Therapeutics, Nikolai Naryshkin, Chief Scientific Officer, Ribonaut Therapeutics, Paige Diamond, Senior Investigator, Interdict Bio, Peng Yue, Co-Founder and Chief Executive Officer, ReviR Therapeutics, Perla Breccia, Senior Director of Chemistry, Astex Pharmaceuticals, Shunichi Kashida, Co-Founder, Representative Director, President and CEO, xFOREST Therapeutics Co. Ltd., Stephan Eismann, Head of Machine Learning, Atomic AI, Thomas Wynn, Director of Medicinal Chemistry, Rgenta Therapeutics Inc., Yaqiang Wang, Assistant Professor, Medical College of Wisconsin Category: Conferences | Science, Health and Medicine | Pharmaceuticals Date and Time: 2nd December 2025 at 7:00 am to 4th December 2025 at 6:00 pm Venue details: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States